Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for development, including conducting clinical studies in cholestatic indications.
Product Name : LUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2021
Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Mirum will utilize EVERSANA’s commercialization platform to provide integrated nationwide distribution, specialty pharmacy, patient services and Hub support for maralixibat, if approved.
Product Name : LUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 15, 2020
Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership